Article info
PDFLetters
Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection
- Correspondence to Dr Dimitrios Vassilopoulos, 2nd Department of Medicine, Hippokration General Hospital, Athens University School of Medicine, 114 Vass. Sophias Ave., Athens 115 27, Greece; dvassilop{at}med.uoa.gr
Citation
Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection
Publication history
- Received May 25, 2012
- Revised July 27, 2012
- Accepted August 2, 2012
- First published August 28, 2012.
Online issue publication
April 13, 2016
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions